Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Private equity firm jumps into vascular health with new investment
Vascular Technology, first founded 40 years ago, is planning on using the new funds to grow and expand its portfolio.
New report raises questions about data that helped heart drug gain FDA approval
Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.
Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease
Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.
Angiographic catheters recalled due to safety risk
The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use.
FDA clears blood clot removal system for treating pulmonary embolism
The Aventus Thrombectomy System was already cleared to treat blood clots in the peripheral arteries. This latest approval comes after positive results from an IDE study were published in JSCAI.

Medtronic has received FDA approval for its IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

FDA says treating PAD with paclitaxel-coated devices does not increase mortality risk

After warning healthcare providers about a heightened risk of mortality back in 2019, the FDA has now updated its stance on the use of these devices.

Heart failure symptoms after PCI increase risk of adverse events

Researchers in Japan tracked BNP levels and bleeding events among more than 7,000 PCI patients. The group noted that managing heart failure in the first 30 days after PCI can help boost outcomes.

Balloon expansion deployment of an Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device.

TAVR vs. surgery: Exploring 5-year outcomes among intermediate-risk patients

A group of renowned TAVR specialists examined data from 783 pairs of intermediate-risk patients, sharing their findings in the Journal of the American College of Cardiology.

FDA announces recall of more than 250,000 interventional devices due to risk of catheter separation

The FDA has said this is a Class I recall, which means using the devices “may cause serious injuries or death.” A total of 18 injuries have been reported so far.

Private equity-backed cardiology group continues busy year with acquisition of Florida practice

Cardiovascular Associates of America, which has already had an eventful 2023, announced a new acquisition that helps expand its footprint in the Sunshine State.

The Surdonics SurVeil drug-coated balloon to treat peripheral artery disease.

FDA approves next-gen DCB, earning the manufacturer a $27M payment from Abbott

The new-look DCB was designed to provide care with a significantly lower drug load than similar devices.

Cardiologist agrees to pay $5M for overstating heart findings to justify unnecessary procedures

The North Carolina physician allegedly performed unnecessary atherectomy procedures to treat minor blockages in the leg arteries of multiple patients.

The Surmodics Pounce Thrombectomy System

FDA clears new ‘grab-and-go’ interventional device for below-the-knee blood clot removal

The new device was designed to remove thrombi and emboli from peripheral arteries ranging from 2 to 4 mm.

Vascular & Endovascular

Private equity firm jumps into vascular health with new investment

New report raises questions about data that helped heart drug gain FDA approval

Popular obesity drugs limit amputations, heart issues among patients with peripheral artery disease

Angiographic catheters recalled due to safety risk

FDA clears blood clot removal system for treating pulmonary embolism